2021-01-04,"b'USA stocks with worst weekly price performance on Stock Target Advisor https://t.co/F4i3VqKZ25 on 2021-01-04 : $ARCT, $RARE, $EDIT, $MRNA, $SGMO'"
2021-01-04,"b""@MaxPowerNGS @genxyzc Bought my $SGMO back at the end of day last week, sold my $JNJ. Interesting that it has such a nice pop at open in premarket, still don't understand $BNGO, but gene therapy will have it's day in the sun like $PLUG, $NIO, $GNRC and $TSLA will rise as energy future plays."""
2021-01-04,b'$SGMO indecision triangle break out target line https://t.co/rLvRDfo8WU'
2021-01-04,"b'RT @mchilberg: @_B_I_O_T_E_C_H_ The CRISPR-Cas9 system is inherently more prone to off-target effects compared to ZFNs or TALENs, because t\xe2\x80\xa6'"
2021-01-04,b'RT @MaxPowerNGS: @roscoesinjin @GamalielBaer @stefanomjr @_B_I_O_T_E_C_H_ @jq1234t $SGMO has a fifth of the valuation of $CRSP ($11B+)...\n$\xe2\x80\xa6'
2021-01-04,"b""RT @mchilberg: Took a quick look at $SGMO catalysts for C21.  Still rough so let me know if I've missed any.  WAG not on list:  New collab\xe2\x80\xa6"""
2021-01-04,"b'RT @mchilberg: @_B_I_O_T_E_C_H_ The CRISPR-Cas9 system is inherently more prone to off-target effects compared to ZFNs or TALENs, because t\xe2\x80\xa6'"
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,b'RT @Biotech2050: $ZIOP $PGEN $ATNM $KPTI $CRMD $SGMO\n@SangamoTx @Precigen @Karyopharm @ActiniumPharma @ziopharm  \n\nAdd on your undervalued\xe2\x80\xa6'
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,b'RT @Biotech2050: $ZIOP $PGEN $ATNM $KPTI $CRMD $SGMO\n@SangamoTx @Precigen @Karyopharm @ActiniumPharma @ziopharm  \n\nAdd on your undervalued\xe2\x80\xa6'
2021-01-04,b'RT @Biotech2050: $ZIOP $PGEN $ATNM $KPTI $CRMD $SGMO\n@SangamoTx @Precigen @Karyopharm @ActiniumPharma @ziopharm  \n\nAdd on your undervalued\xe2\x80\xa6'
2021-01-04,b'$ZIOP $PGEN $ATNM $KPTI $CRMD $SGMO\n@SangamoTx @Precigen @Karyopharm @ActiniumPharma @ziopharm  \n\nAdd on your undervalued pre-clinical thro\xe2\x80\x99 phase 3 company trading at sub $1.5B market cap (Value per Jeffries) via a response to this tweet.\n\nRT if you own one of the above. https://t.co/tuKITosZxx'
2021-01-04,b'@Pharmdca I own $TRIL and $PDSB.. $KPTI is on the buy list.. so none of the gene editing bios $NTLA $SGMO and $EDIT'
2021-01-04,b'RT @wyv_123: Reasonable chance we see same panic buying in biotech by big pharma who could have picked them up for cheap last 1-2 years but\xe2\x80\xa6'
2021-01-04,b'@PersimmonTI Also $sgmo didn\xe2\x80\x99t exactly run this year...few weeks ago it was 9. Shorts got scared a bit when Sandy said he was open to a BO'
2021-01-04,"b'@PersimmonTI Do the other crisper companies have this many partnerships with big pharma along with increasing revenue? $sgmo still has a small market relative to $crsp. I want the most precise safest, least immunogenicity in this field...off target editing issues seems no bueno. https://t.co/G941V1TwNt'"
2021-01-04,b'Top losers 12/31\n$CPSH\n$SRTS\n$ENOB\n$SYRS\n$ENLV\n$OSTK\n$GRIL\n$MICT\n$EDIT\n$AMTI\n$FTEK\n$PCVX\n$GNW\n$ADVM\n$GBIO\n$CBAT\n$BYSI\n$CLLS\n$GNCA\n$BRKS\n$JRJC\n$MYT\n$VIRI\n$LSF\n$CCCC\n$NBAC\n$FULC\n$GBR\n$ORIC\n$ESPR\n$OPTT\n$GRVY\n$MTNB\n$TRIT\n$PRPH\n$PRT\n$SGMO\n$NTN\n$PHUN\n$CAPR\n$JG\n$MCF\n$SVRA\n$SCPS\n$ONVO'
2021-01-04,"b'RT @mchilberg: @MaxPowerNGS Again mentions how $SGMO has control of IP, smaller footprint, better multiplex editing and targeting advantage\xe2\x80\xa6'"
2021-01-04,b'RT @Alex59834045: @LuoshengPeng How about $SGMO? I have friends in biotech in San Diego and they tell me this is the one to watch out for.'
2021-01-04,"b'RT @biostonks: If you haven\xe2\x80\x99t joined a cult, you should look into it \xf0\x9f\x98\x82. I am a proud member of the $SGMO $OCUL $MYOV cult'"
2021-01-04,"b'RT @firehorsecaper: Cathie Wood, ARK Funds CIO is a big owner (&gt;10%) of $CRSP it has a 9.3% weighting in ARK Gen and 6.05% in ARK Innov. I\xe2\x80\xa6'"
2021-01-04,b'RT @DHopkins9975: Aggressive price target but riding the hot hand in Gene editing. Going with $SGMO. Hopefully it fairs better than $BCLI t\xe2\x80\xa6'
2021-01-04,b'RT @wyv_123: Reasonable chance we see same panic buying in biotech by big pharma who could have picked them up for cheap last 1-2 years but\xe2\x80\xa6'
2021-01-04,b'Reasonable chance we see same panic buying in biotech by big pharma who could have picked them up for cheap last 1-2 years but now will have to FOMO pay up. $XBI $TRIL $EDIT $CRIS $TCON $MREO $SGMO $PFE $BMY $MRK $LLY https://t.co/xVvXf12Uki'
2021-01-04,b'RT @Alex59834045: @LuoshengPeng How about $SGMO? I have friends in biotech in San Diego and they tell me this is the one to watch out for.'
2021-01-04,b'RT @cmclark43: $GOOGL $DOW $MSFT $AAPL $ZM $ZS $AMD $M $TSLA #MUSK $GLD $SLV $TVIX $CRSP $SGMO $NFLX $DIS $GOOGL $FB $IBM $NVDA $PPLT $CLDR\xe2\x80\xa6'
2021-01-04,b'Aggressive price target but riding the hot hand in Gene editing. Going with $SGMO. Hopefully it fairs better than $BCLI this past year! Thanks @pawcio2009 for running this. https://t.co/Gn0IqmLvdD'
2021-01-03,"b'Cathie Wood, ARK Funds CIO is a big owner (&gt;10%) of $CRSP it has a 9.3% weighting in ARK Gen and 6.05% in ARK Innov. I would love to know if she vetted $SGMO for the fund. Sangamo is 20% of the size of $CRSP and would be a good diversification play in the space, tech and IP.'"
2021-01-03,b'@Finance_d0ct0r @TheMarkCooke @ARKInvest Thoughts on $bngo? Or $sgmo'
2021-01-03,b'$GOOGL $DOW $MSFT $AAPL $ZM $ZS $AMD $M $TSLA #MUSK $GLD $SLV $TVIX $CRSP $SGMO $NFLX $DIS $GOOGL $FB $IBM $NVDA $PPLT $CLDR $OKTA $SNOW $NNOX $AMC $T $NOK $GE $CAT  $SPY $ORCL $COST $AMZN $WMT #COVID #VACCINE #MRNA $PFE $NVAX #TRUMP #MAGA https://t.co/ZdyvpxoxgH'
2021-01-03,b'@PersimmonTI @pawcio2009 @_B_I_O_T_E_C_H_ $SGMO a very reasonable selection by @_B_I_O_T_E_C_H_ - @PersimmonTI how about yours?'
2021-01-03,"b""@PersimmonTI Given the correlation to the CRISPR players, I think $SGMO will tank when they do. When those gene reg &amp; CAR-Treg programs make their way into the clinic, I'll buy in again. Otherwise, I'll keep trading the range."""
2021-01-03,"b'@snicobio @avidresearch @PersimmonTI Agreed, and I think there is great potential in targeted epigenomic regulation. I wonder if $SGMO ZNF will have any competitive edge in that area than over dCas9+epigenomic regulator fusion proteins.'"
2021-01-03,"b""Biotech '21 Watchlist \n$Crspr $ilmn $pacb $ntla \n$Edit $Glsi $Blue $scps $glsi \n$Sgmo $Uthr $Vrtx \n\nI feel like a lot of attention will be put on bio tech moving forward.The worlds main focus should clearly be on our health and how we can prevent a repeat of 2020. Share your WL!"""
2021-01-03,"b'@avidresearch @PersimmonTI $SGMO isn\xe2\x80\x99t really a gene editing company anymore. Seems to be transitioning to epigenome editing. Tech has always been amazing, but couldn\xe2\x80\x99t beat the CRISPR craze.'"
2021-01-03,"b'$SGMO $DTIL\n\nThe question for the gene editing \xe2\x80\x9cvalue\xe2\x80\x9d picks is, \n\nif the \xe2\x80\x9cbubble\xe2\x80\x9d bursts, do they go down with the rest, anyway?'"
2021-01-03,"b'RT @mchilberg: Keep an eye open for publication of this article.  Would love to learn about Megan Levings work on ""luxury CAR #Tregs and im\xe2\x80\xa6'"
2021-01-03,"b'Keep an eye open for publication of this article.  Would love to learn about Megan Levings work on ""luxury CAR #Tregs and impact on cancer. $SGMO\nhttps://t.co/75oTzHgWH7'"
2021-01-03,b'RT @Alex59834045: @LuoshengPeng How about $SGMO? I have friends in biotech in San Diego and they tell me this is the one to watch out for.'
2021-01-03,b'@DolphfredC @Molino70577916 @JRambo0810 I left about 10k $coty  shares and will add more on dips. I\xe2\x80\x99m heavy in biotech now $kpti $kala $nmtr $itrm $sgmo $phas and many many others'
2021-01-03,"b""I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the changes at the end of each week in 21'. $VRTX $SRPT $EXAS $CRSP $RARE $ARWR $BBIO $RCKT $EDIT $BLUE $SGMO $QURE $RGNX $FLGT $ZIOP $VYGR $SIOX $ABEO https://t.co/I0ROS0RjAq"""
2021-01-03,b'RT @ADBYNOT: M actionable setups:\n3-1: $VAPO \nInside + W setups: $NTES $APPN  $APVO $FUTU $XPEV $AVTR $NIO \nInside + D setups: $FB $MSFT $C\xe2\x80\xa6'
2021-01-03,b'RT @ADBYNOT: M actionable setups:\n3-1: $VAPO \nInside + W setups: $NTES $APPN  $APVO $FUTU $XPEV $AVTR $NIO \nInside + D setups: $FB $MSFT $C\xe2\x80\xa6'
2021-01-03,b'And what about $SGMO? Like idea of $GILD getting taken out to rescue from present suboptimal performance!!!! https://t.co/G8AKyCYAKX'
2021-01-03,b'M actionable setups:\n3-1: $VAPO \nInside + W setups: $NTES $APPN  $APVO $FUTU $XPEV $AVTR $NIO \nInside + D setups: $FB $MSFT $CARR $ELAN $KZIA \nOutside + W setups: $FEYE $APTO \nOutside + D setups: $LAC\nRest of Green M setups:\n$ARRY $TTCF $NEE $ONVO $SGMO $TREE'
2021-01-03,"b'If you haven\xe2\x80\x99t joined a cult, you should look into it \xf0\x9f\x98\x82. I am a proud member of the $SGMO $OCUL $MYOV cult https://t.co/UhkIuuhoKn'"
2021-01-03,b'RT @Biotech2050: @Biohazard3737 This will all change if biopharma embrace the vision of @UrnovFyodor (video below). Turning acute diseases\xe2\x80\xa6'
2021-01-03,b'@Biohazard3737 This will all change if biopharma embrace the vision of @UrnovFyodor (video below). Turning acute diseases to cure is not the end game. Upgrading humans just like a smartphone is a multi trillion market opportunity. @SangamoTx @Precigen $SGMO $PGEN \n\nhttps://t.co/eWL3jsjPTh'
2021-01-03,b'RT @Dorman06: $SGMO big monthly breakout on volume. needs over 18.80 before testing old highs https://t.co/IlV56Ma5FT'
2021-01-03,"b'RT @mchilberg: @MaxPowerNGS Again mentions how $SGMO has control of IP, smaller footprint, better multiplex editing and targeting advantage\xe2\x80\xa6'"
2021-01-03,"b""RT @SamRadley4: @biopharmacaster for #5, there is no reason $SGMO goes back to $10. they're willing to entertain a BO and it's highly likel\xe2\x80\xa6"""
2021-01-03,b'RT @Alex59834045: @LuoshengPeng How about $SGMO? I have friends in biotech in San Diego and they tell me this is the one to watch out for.'
2021-01-03,b'Goldman Sachs $GS to acquire significant stake in $CAPC announcement as early as Tuesday\nhttps://t.co/fK8PPZ6hwp\n\n$BLKG $REGI $LPX $INO $JBHT $PPC $AAPT $TCHH $UHLN $LTNC $SGMO $BWP $ORLY'
2021-01-03,"b'RT @mchilberg: @MaxPowerNGS Again mentions how $SGMO has control of IP, smaller footprint, better multiplex editing and targeting advantage\xe2\x80\xa6'"
2021-01-03,b'@LuoshengPeng How about $SGMO? I have friends in biotech in San Diego and they tell me this is the one to watch out for.'
2021-01-03,"b'RT @The_Rump_Rain: $SGMO \n$80 per share, $12 billion\nBefore March\n#2021biobuyout'"
2021-01-02,"b'Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $NOV $FSR $GRWG $CWH $OSTK $MSTR $CDE $SGMO $PGNY $mp https://t.co/k3uyuEbRpJ'"
2021-01-02,"b'RT @mchilberg: @_B_I_O_T_E_C_H_ The CRISPR-Cas9 system is inherently more prone to off-target effects compared to ZFNs or TALENs, because t\xe2\x80\xa6'"
2021-01-02,"b'RT @The_Rump_Rain: $SGMO \n$80 per share, $12 billion\nBefore March\n#2021biobuyout'"
2021-01-02,"b'RT @mchilberg: @_B_I_O_T_E_C_H_ The CRISPR-Cas9 system is inherently more prone to off-target effects compared to ZFNs or TALENs, because t\xe2\x80\xa6'"
2021-01-02,"b'@_B_I_O_T_E_C_H_ @Ruven27 You\xe2\x80\x99re a fan of $SGMO as well, ay?'"
2021-01-02,"b'RT @The_Rump_Rain: $SGMO \n$80 per share, $12 billion\nBefore March\n#2021biobuyout'"
2021-01-02,"b'RT @mchilberg: $NVS is a useful example to consider WRT #ZFN.  They are focused on 3 key areas: AAV therapies, CAR-T and #CRISPR.  Yet they\xe2\x80\xa6'"
2021-01-02,"b'RT @The_Rump_Rain: $SGMO \n$80 per share, $12 billion\nBefore March\n#2021biobuyout'"
2021-01-02,"b'Afternoon Most Tweeted Mid Caps, check out Gambiste Top 10: $NOV $FSR $GRWG $CWH $MSTR $PGNY $OPK $SGMO $OSTK $BMI https://t.co/k3uyuEbRpJ'"
2021-01-02,"b'$SGMO \n$80 per share, $12 billion\nBefore March\n#2021biobuyout'"
2021-01-02,b'@SamRadley4 @marko1332 @_B_I_O_T_E_C_H_ @CasinoCapital This is why there is a large possibility it will happen soon.  $SGMO is currently trading for beans compared to what the company is worth'
2021-01-02,"b""RT @SamRadley4: @biopharmacaster for #5, there is no reason $SGMO goes back to $10. they're willing to entertain a BO and it's highly likel\xe2\x80\xa6"""
2021-01-02,"b'RT @mchilberg: $NVS is a useful example to consider WRT #ZFN.  They are focused on 3 key areas: AAV therapies, CAR-T and #CRISPR.  Yet they\xe2\x80\xa6'"
2021-01-02,b'RT @mchilberg: $SGMO Monthly &amp; Wkly charts updated thru CYE20:\n- W2 1st leg thru resist/retests+ based for 8 mths b4 resuming with energy\n-\xe2\x80\xa6'
2021-01-02,b'RT @mchilberg: $SGMO Monthly &amp; Wkly charts updated thru CYE20:\n- W2 1st leg thru resist/retests+ based for 8 mths b4 resuming with energy\n-\xe2\x80\xa6'
2021-01-02,"b'RT @mchilberg: @MaxPowerNGS Again mentions how $SGMO has control of IP, smaller footprint, better multiplex editing and targeting advantage\xe2\x80\xa6'"
2021-01-02,b'RT @mchilberg: $SGMO Monthly &amp; Wkly charts updated thru CYE20:\n- W2 1st leg thru resist/retests+ based for 8 mths b4 resuming with energy\n-\xe2\x80\xa6'
2021-01-02,b'RT @mchilberg: $SGMO Monthly &amp; Wkly charts updated thru CYE20:\n- W2 1st leg thru resist/retests+ based for 8 mths b4 resuming with energy\n-\xe2\x80\xa6'
2021-01-02,b'RT @mchilberg: $SGMO Monthly &amp; Wkly charts updated thru CYE20:\n- W2 1st leg thru resist/retests+ based for 8 mths b4 resuming with energy\n-\xe2\x80\xa6'
2021-01-02,"b""RT @SamRadley4: @biopharmacaster for #5, there is no reason $SGMO goes back to $10. they're willing to entertain a BO and it's highly likel\xe2\x80\xa6"""
2021-01-02,"b'RT @mchilberg: $NVS is a useful example to consider WRT #ZFN.  They are focused on 3 key areas: AAV therapies, CAR-T and #CRISPR.  Yet they\xe2\x80\xa6'"
2021-01-02,b'$SGMO Monthly &amp; Wkly charts updated thru CYE20:\n- W2 1st leg thru resist/retests+ based for 8 mths b4 resuming with energy\n- W3 1st leg thru ceiling (no wick) w/2nd step b4 basing for 2 mths and resuming to new high\n- W4 1st leg thru resistance close at $15.60\nsupport $15/$14/$12 https://t.co/peWJ11pLoM https://t.co/BIvGMgLyrv'
2021-01-02,"b""@biopharmacaster for #5, there is no reason $SGMO goes back to $10. they're willing to entertain a BO and it's highly likely it happens. MM's can push it down but it will showcase new support."""
2021-01-02,"b""$NVS is a useful example to consider WRT #ZFN.  They are focused on 3 key areas: AAV therapies, CAR-T and #CRISPR.  Yet they signed significant collab with $SGMO for #CNS.  They can't pursue ZFN on their own due to IP moat but collab given them first hand view of ZFP + delivery https://t.co/nVhgc5NaeD"""
2021-01-02,"b'@_B_I_O_T_E_C_H_ @CasinoCapital $SGMO $EDIT $CRSP $NTLA together easily over 250bn in 2021 is my bet. Genomics will be the next hype in row with AI, Self-Driving, DeFi and other mass trends. I try to keep telling folks hodl the CRSP shares at 100$, I think we will see 1.000 in 2021 or 2022.'"
2021-01-02,b'RT @MaxPowerNGS: $SGMO longs have been saying this for a long time. \n\n#CRISPR is inherently permissive and the off-targets are evolutionari\xe2\x80\xa6'
2021-01-02,b'RT @MaxPowerNGS: $SGMO longs have been saying this for a long time. \n\n#CRISPR is inherently permissive and the off-targets are evolutionari\xe2\x80\xa6'
2021-01-02,b'RT @The_Rump_Rain: $EDIT $CRSP $NTLA all dropped in final minutes today while $SGMO gained 1.5%. Smart money quit while they were ahead and\xe2\x80\xa6'
2021-01-02,b'RT @The_Rump_Rain: @MacroMarkets_ I doubt it was even a dirty inside trade CRSP is obviously not worth 12b.   Oh and $SGMO owns patents to\xe2\x80\xa6'
2021-01-02,"b'@MaxPowerNGS Again mentions how $SGMO has control of IP, smaller footprint, better multiplex editing and targeting advantage today.  All add value to an acquirer.'"
2021-01-02,b'RT @Biotech2050: #biopick2021 deadline is today. Come in and participate . Please RT. $SGMO $ZIOP $PGEN $TGTX $BMYRT $BMY $ACAD $IBB $XBI $\xe2\x80\xa6'
2021-01-02,"b'$SGMO in Downtrend: its price may drop because broke its higher Bollinger Band on December 22, 2020. View odds for this and other indicators: https://t.co/FQL7Mc81RL #SangamoTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/HZ4b9bdib2'"
2021-01-02,"b'4. $kzia trading at 8.40 sees 13 again in the first half of 2021\n5. $sgmo trading at 15 plus drifts back to 10 again during 1h\n6. $cala goes one for two win for both programs, stock probably at 15+ 1h\n7. $soly gets fda approval for cellulite stock pops pm but drifts back down'"
2021-01-02,b'RT @MaxPowerNGS: $SGMO longs have been saying this for a long time. \n\n#CRISPR is inherently permissive and the off-targets are evolutionari\xe2\x80\xa6'
2021-01-02,b'RT @MaxPowerNGS: $SGMO longs have been saying this for a long time. \n\n#CRISPR is inherently permissive and the off-targets are evolutionari\xe2\x80\xa6'
2021-01-02,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2021-01-02,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2021-01-02,"b'#biopick2021 deadline is today. Come in and participate . Please RT. $SGMO $ZIOP $PGEN $TGTX $BMYRT $BMY $ACAD $IBB $XBI $KPTI $CRMD $ATNM $XLRN ...., $.... https://t.co/YDkAei1mGp'"
2021-01-02,"b""@mukund @gtcalpha ...vs a therapeutics company which could be using AI/ML to discover new drug targets or to design novel drugs.  These companies don't even need to be in the 'genomics' space at all.  Then of course you have gene editing companies like $CRSP, $SGMO, $EDIT, etc."""
2021-01-02,b'@saxena_puru @mark_ungewitter i agree with the idea. i think owning top dogs $CRSP $PACB and others that own patents is worth the due diligence and added risk compared with a broad index as they have potential for continued massive breakouts in a very short period of time. Long $PACB $CRSP $SGMO'
2021-01-02,"b'$SGMO, $SJM and $MDLA identified by our stock screener as being in a weinstein stage 1 setup phase. https://t.co/QPBqOMq9hD'"
2021-01-02,b'RT @mchilberg: $PFE requesting proposals for academic research.  Specifically called #Celltherapy and protein aggregation clearing out of s\xe2\x80\xa6'
2021-01-01,b'RT @Dorman06: $SGMO big monthly breakout on volume. needs over 18.80 before testing old highs https://t.co/IlV56Ma5FT'
2021-01-01,b'RT @Dorman06: $SGMO big monthly breakout on volume. needs over 18.80 before testing old highs https://t.co/IlV56Ma5FT'
2021-01-01,"b'$MRK Confirmation On New Partnership Agreement With Fortune 500 Company, Announcement Imminent \nhttps://t.co/Mv3xmUJu9A\n\n$BLKG $REGI $LPX $INO $JBHT $PPC $AAPT $TCHH $UHLN $LTNC $SGMO $BWP $ORLY'"
2021-01-01,b'$BLUE \xf0\x9f\xa4\xb7\xe2\x80\x8d\xe2\x99\x82\xef\xb8\x8f \n$PSTX all profits there so I\xe2\x80\x99ll hold through data \n$SGMO lonnnng\n$FSDC like this one \n$IMTX dunno yet \n\nNext year I\xe2\x80\x99m going to be shifting mostly into gene tx plays. I\xe2\x80\x99ve provided lists of most from 0-10B'
2021-01-01,"b'Investing wise, 2020 was a great year for me (+61%). It can be hard keeping up with investments during the school year but I feel like most of my trades were sound. Major winners long were $MYOV $OCUL $VCEL $GTHX $SGMO $PSNL and SPACs $IPOC $LCA $SPCE $DKNG https://t.co/HwrWx2s5LS'"
2021-01-01,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2021-01-01,b'RT @_B_I_O_T_E_C_H_: $SGMO further catalysts 2021:\nstart allogeneic CAR-T trial with $KITE $GILD\nreport #sickle #cell data with $SNY (likel\xe2\x80\xa6'
2021-01-01,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2021-01-01,b'RT @_B_I_O_T_E_C_H_: BLAIR Selected Catalysts for Gene/Cell Therapy and\n#Gene #Editing Companies\n$SGMO File IND for ST-501 for tauopathies\xe2\x80\xa6'
2021-01-01,b'RT @_B_I_O_T_E_C_H_: $SGMO further catalysts 2021:\nstart allogeneic CAR-T trial with $KITE $GILD\nreport #sickle #cell data with $SNY (likel\xe2\x80\xa6'
2021-01-01,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2021-01-01,b'RT @mchilberg: Commented on $SGMO - Genomic Medicine: Slowly Moving To All At Once. https://t.co/f2F49ihyHV'
2021-01-01,b'RT @mchilberg: $PFE requesting proposals for academic research.  Specifically called #Celltherapy and protein aggregation clearing out of s\xe2\x80\xa6'
2021-01-01,b'RT @Biotech2050: Which company updates are you waiting most from #JPM21 ?\nA. $SGMO $PGEN $ZIOP\nB. $KPTI $TGTX $ACAD \n\nIf other companies in\xe2\x80\xa6'
2021-01-01,b'$PFE requesting proposals for academic research.  Specifically called #Celltherapy and protein aggregation clearing out of scope which is consistent with internal work in those areas.  $SGMO\nhttps://t.co/wMizMzgbCs https://t.co/b91AY9A9fo'
2021-01-01,b'RT @mchilberg: Commented on $SGMO - Genomic Medicine: Slowly Moving To All At Once. https://t.co/f2F49ihyHV'
2021-01-01,b'RT @ProfitTradeRoom: 4 Alerted trades today - 4 Winners \xf0\x9f\x8e\xaf x 4\xef\xb8\x8f\xe2\x83\xa3\n\nPerfect score and a great total \xe2\x9c\x85\xf0\x9f\x92\xb8\n\n2 Buys on $SLS power squeezer!\n\n#Fresh\xe2\x80\xa6'
2021-01-01,b'RT @ProfitTradeRoom: 4 Alerted trades today - 4 Winners \xf0\x9f\x8e\xaf x 4\xef\xb8\x8f\xe2\x83\xa3\n\nPerfect score and a great total \xe2\x9c\x85\xf0\x9f\x92\xb8\n\n2 Buys on $SLS power squeezer!\n\n#Fresh\xe2\x80\xa6'
2021-01-01,b'RT @ProfitTradeRoom: $SGMO and $NETE both $14 in competition who makes it higher'
2021-01-01,b'Commented on $SGMO - Genomic Medicine: Slowly Moving To All At Once. https://t.co/f2F49ihyHV'
2021-01-01,b'$SGMO big monthly breakout on volume. needs over 18.80 before testing old highs https://t.co/IlV56Ma5FT'
2021-01-01,"b'SANGAMO THERAPEUTICS is processing as a trademark filing by Sangamo Therapeutics, Inc. https://t.co/Ny4BUFmthT #SANGAMOTHERAPEUTICS $SGMO #SANGAMO #THERAPEUTICS https://t.co/cpBFaLCLXV'"
2021-01-01,"b'SANGAMO THERAPEUTICS under pending registered trademark approval. Application by Sangamo Therapeutics, Inc. https://t.co/scSNhss9kT #SANGAMOTHERAPEUTICS $SGMO #SANGAMO #THERAPEUTICS https://t.co/Pgz2eGeSdD'"
2021-01-01,b'RT @_B_I_O_T_E_C_H_: Tru ist Biotech: $XBI Stocks to own into 2021\n$BTAI $ATNX $FATE $NMTR $CNST \n$QURE $REGN $SGMO $DRNA https://t.co/hexG\xe2\x80\xa6'
2021-01-01,"b'Year ending with $ESTC, $SE, $PINS, $SQ, $VRM, $SKLZ, $ROKU, $TDOC, $NET, $NVTA, $FSLY, $ETSY \nBio - $MYOV, $AUPH, $TCON, $OCUL, $KPTI, $SGMO, $MREO, $SIOX. - 2021, Bios would get more allocations in new capital. I see too much pump and dump in tech and SPACs are market spoilers.'"
2020-12-31,"b'Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $OSTK $FUTU $HYLN $PRPL $AXSM $CWH $MAXR $SGMO $GRWG https://t.co/k3uyuEbRpJ'"
2020-12-31,"b""@mattyjc @thegunnerab I never put a price target. I'm glad whe patients are cured and the proper price will follow with $SGMO or any other biotech I own."""
2020-12-31,"b'@thegunnerab @mattyjc Sold a few out of the money calls lately, but this sector will get some mojo after JPM in 2021. I was surprised on the power and swiftness of latest 50% gain, but we know $SGMO is a long term winner.'"
2020-12-31,b'RT @yusufhameed: @thegunnerab But great for those who sold $SGMO at $17 to 18 this week only to get at a nice discount today. \xf0\x9f\x98\x89\xf0\x9f\x94\xa5\xe2\x98\x80\xef\xb8\x8f'
2020-12-31,b'@thegunnerab But great for those who sold $SGMO at $17 to 18 this week only to get at a nice discount today. \xf0\x9f\x98\x89\xf0\x9f\x94\xa5\xe2\x98\x80\xef\xb8\x8f'
2020-12-31,b'Trndg \xe2\x86\x97  $FLDM $AMRS $REAL $CYDY $SGMO $CAN $BTBT website @ https://t.co/2GYk1BC0Nr #DayTrading #stocks #StocksToTrade  #trading #investing #stockstowatch'
2020-12-31,b'@_B_I_O_T_E_C_H_ Added to $SGMO 15.50s end of year gift'
2020-12-31,b'$SGMO I tried to warn you guys they will love to close this under $15 for Opex in two weeks time.\n\nCompletely corrupt WS...'
2020-12-31,"b""RT @InvestorVenture: $APT\nI Haven't BEEN MORE CONFIDENT on any other Play!\n\n$AHPI $LAKE $OPK $KODK $BVXV $CODX $ALT $EARS $ADMA $IBIO $ABT\xe2\x80\xa6"""
2020-12-31,"b""$SPY  $BA $SGMO $GNOG $BFT $LCY into '21  Wishing everyone a great 2021.  Please be careful and don't act crazy today.  The pandemic is not over. The next few months are still going to be dangerous. \n\nRemember Georgia ele... https://t.co/Nn9HDr41qJ"""
2020-12-31,b'@TW_0317 the entire sector is down. nothing unique to $SGMO'
2020-12-31,"b""$APT\nI Haven't BEEN MORE CONFIDENT on any other Play!\n\n$AHPI $LAKE $OPK $KODK $BVXV $CODX $ALT $EARS $ADMA $IBIO $ABT $BNTX $AIM $BMRA $ABIO $APM $BCRX $SGBX $VBIV $VXRT $SRNE $MRNA $NVAX $INO $GILD $DVAX $QDEL $ABBV $AZN $VERU $PFE $MRK $JNJ $CRSP $SGMO $AMRN $TRVN $AAPL $AMZN https://t.co/UWT8FchOqp https://t.co/K5aWn4MVn8"""
2020-12-31,b'$sgmo. Down 5% today right now and my biggest loser out of 30 stocks. Tough one to figure. Long large.'
2020-12-31,b'@BoisselStephane We you a prosperous 2021 Stephane. You left $SGMO and we have so many unanswered questions on CART TREGS + xenotransplantation potential. Any chance you can enlighten us?'
2020-12-31,b'RT @Biotech2050: $SGMO @SangamoTx @TxCellSA #xenotransplantation #transplant #GVHD #autoimmunediseases #diabetes CAR Tregs #sclerosis #rheu\xe2\x80\xa6'
2020-12-31,"b'RT @Biotech2050: @SangamoTx @BoisselStephane @mito_gene #4\nVision 2030. \nZFN2.0 + #xenotransplantation + CAR Tregs + ""infinite pipeline"" ca\xe2\x80\xa6'"
2020-12-31,b'RT @Biotech2050: @_B_I_O_T_E_C_H_ @ByMadeleineA @SangamoTx @BoisselStephane In this video (link below) George Church says that if we were t\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: dumped $KPTI for tax loss\nadded $SGMO 16.00  on gap close'
2020-12-31,b'Added $SGMO shares $16.04 and look forward to January after consolidation'
2020-12-31,b'@andrewross11 Andrew. Happy New Year! Any view on $SGMO good or bad? Zinc finger tech and IP (patents).'
2020-12-31,b'$sgmo back to its old self after a nice run recently'
2020-12-31,b'RT @BobMarshall63: FWIW changes in LT account - large positions in order: $TGTX $AXSM $DMTK $IPOC $SGMO $XAIR $BTAI $OCUL $KALA $ONCT $TCON\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: BLAIR Selected Catalysts for Gene/Cell Therapy and\n#Gene #Editing Companies\n$SGMO File IND for ST-501 for tauopathies\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: $SGMO further catalysts 2021:\nstart allogeneic CAR-T trial with $KITE $GILD\nreport #sickle #cell data with $SNY (likel\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: BLAIR Selected Catalysts for Gene/Cell Therapy and\n#Gene #Editing Companies\n$SGMO File IND for ST-501 for tauopathies\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,"b'@Ruven27 whatever,  needed to go all in $SGMO anyway'"
2020-12-31,"b'REVERSALtoDOWN: $SGMO Sangamo Therapeutics, Inc https://t.co/tqchtinnIB \xf0\x9f\x93\x89 \xf0\x9f\x94\x9c TradeIdeas via \xe2\x9f\xb6 https://t.co/ZgCyz4rX3x'"
2020-12-31,b'RT @_B_I_O_T_E_C_H_: dumped $KPTI for tax loss\nadded $SGMO 16.00  on gap close'
2020-12-31,b'dumped $KPTI for tax loss\nadded $SGMO 16.00  on gap close'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,"b'@_B_I_O_T_E_C_H_ @lblegend33 what is ""it""? $SGMO?'"
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,b'RT @Biotech2050: Good morning America \xf0\x9f\x87\xba\xf0\x9f\x87\xb8 \n\nWhat a fantastic year this has been for biotech. $BMYRT could give us a Happier Ending.\n$TGTX $H\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,"b""@_B_I_O_T_E_C_H_ No Problem. $SGMO led me to you. Anything ARK has potential to buy appears to be a sure thing in these markets. I think $BNGO could head a lot higher. If you have anything in the Gene Editing world that is quiet I'd love to take a peek! GLTU!"""
2020-12-31,b'RT @_B_I_O_T_E_C_H_: $SGMO further catalysts 2021:\nstart allogeneic CAR-T trial with $KITE $GILD\nreport #sickle #cell data with $SNY (likel\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: $SGMO further catalysts 2021:\nstart allogeneic CAR-T trial with $KITE $GILD\nreport #sickle #cell data with $SNY (likel\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: BLAIR Selected Catalysts for Gene/Cell Therapy and\n#Gene #Editing Companies\n$SGMO File IND for ST-501 for tauopathies\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,b'RT @_B_I_O_T_E_C_H_: Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could s\xe2\x80\xa6'
2020-12-31,b'$SGMO further catalysts 2021:\nstart allogeneic CAR-T trial with $KITE $GILD\nreport #sickle #cell data with $SNY (likely march)\nreport Hemophilia Data with $PFE\nstart in vivo gene editing trial with ZFN 2.0\nstart #Tregs trial for organ transplants\nand more....'
2020-12-31,b'BLAIR Selected Catalysts for Gene/Cell Therapy and\n#Gene #Editing Companies\n$SGMO File IND for ST-501 for tauopathies\n(#Alzheimer disease)\nFile IND for ST-101 for #PKU\nReport initial data from phase I/II trial\nof ST-920 for #Fabry disease\nblair missed a few catalysts...following:'
2020-12-31,b'Blair sees #Gene #Editing Accelerate in 2021\nThe drastic difference in performance between LV and gene editing could signify a shift in investor sentiment in future of technology used for cell therapy and de-risked clinical data from gene editing players.\n$SGMO $EDIT $NTLA $CRSP'
2020-12-31,b'RT @BobMarshall63: FWIW changes in LT account - large positions in order: $TGTX $AXSM $DMTK $IPOC $SGMO $XAIR $BTAI $OCUL $KALA $ONCT $TCON\xe2\x80\xa6'
2020-12-31,b'Good morning America \xf0\x9f\x87\xba\xf0\x9f\x87\xb8 \n\nWhat a fantastic year this has been for biotech. $BMYRT could give us a Happier Ending.\n$TGTX $HALO $ACAD $XLRN $PGEN $SGMO my stars of 2020 https://t.co/DMbpSStei4'
2020-12-31,"b'$SGMO, $MGEN and $SDGR all in the Weinstein stage 1 setup phase according to our stock screener. https://t.co/QPBqOMq9hD'"
2020-12-31,"b'RT @FibroMusic: @hiddensmallcaps Hey unrelated, but what are your thoughts on $SGMO if you don\xe2\x80\x99t mind?'"
2020-12-31,"b'@hiddensmallcaps Hey unrelated, but what are your thoughts on $SGMO if you don\xe2\x80\x99t mind?'"
2020-12-31,"b""$SGMO:\n\nNew Insider Filing on SANGAMO THERAPEUTICS, INC's\n\nEVP, Technical Operations\n\nROLF ANDREW RAMELMEIER:\n\nhttps://t.co/LNPZchpRnS"""
2020-12-31,"b""Social media must think I have Fabry after weeks of Migalastat ads on Facebook I'm now flooded with ads to enroll in $avro's study. Haven't noticed if $qure $sgmo and $frln are targeting me on other social media."""
2020-12-31,b'RT @MWOSU1: @TuronianHighs @stockdaddy6 @LuoshengPeng This is a great conversation. What about the value $BNGO could bring to one of the ge\xe2\x80\xa6'
2020-12-31,b'$SGMO New Form 4 for Sangamo Therapeutics\nFrom our Stock News Alerts App'
2020-12-31,"b'@TuronianHighs @stockdaddy6 @LuoshengPeng This is a great conversation. What about the value $BNGO could bring to one of the gene editing companies? $CRSP, $EDIT, $NTLA or even $SGMO?  Just thinking out loud.'"
2020-12-31,b'$SGMO new insider selling: 3331 shares. https://t.co/BVtnO9J2wM'
2020-12-31,"b'Insider Rolf Andrew Ramelmeier reports selling 3,331 shares of $SGMO for a total cost of $60,391.03 https://t.co/32z4hliMEr'"
2020-12-31,"b'#FWSells $SGMO Ramelmeier Rolf Andrew, EVP, Technical Operations of SANGAMO THERAPEUTICS, INC sold 3,331 shares on 2020-12-24. https://t.co/peNIgkJb18'"
2020-12-31,"b'@The_Rump_Rain Except that zinc fingers have failed all their clinical trials so far while CRISPR has very strong data in its phase 1 trial of Beta Thalassemia, Sickle Cell and CAR-T. If we are keeping score its $CRSP 3 $SGMO 0 on successful trials.'"
2020-12-30,b'RT @biostonks: Gene tx players 1-10B mkt cap $NTRA $NVTA $ARWR $FATE $BBIO $IOVA $EDIT $PTCT $PACB $ALLO $NTLA $CDNA $ALKS $RCKT $NSTG $BLU\xe2\x80\xa6'
2020-12-30,"b'@The_Rump_Rain Good luck with that one. Last time I checked no one at $SGMO was anywhere near the invention of CRISPR technology. None of them worked for or with the team that discovered CRISPR. Its owned by Broad Institute and UC Berkely. They licensed it to $CRSP, $EDIT, and $NTLA.'"
2020-12-30,b'@MacroMarkets_ I doubt it was even a dirty inside trade CRSP is obviously not worth 12b.   Oh and $SGMO owns patents to $CRSP $EDIT $NTLA'
2020-12-30,b'RT @MaxPowerNGS: @dkavaichan @Rodmon77 Speaking of Gordon Gecko...the best $SGMO play IMO is a $10B PE buy with an asset breakup. GT to $PF\xe2\x80\xa6'
2020-12-30,b'RT @MaxPowerNGS: @dkavaichan @Rodmon77 Speaking of Gordon Gecko...the best $SGMO play IMO is a $10B PE buy with an asset breakup. GT to $PF\xe2\x80\xa6'
2020-12-30,"b'@B_rizzle87 @iceman_cry $SGMO owns patents to $EDIT $NTLA and $CRSP and their treatment doesn\'t have ""off target"" effects. Pharma Chads will eventually catch on but I don\'t have high expectations in the near term, because people can\'t read'"
2020-12-30,b'@Biotech2k1 $SGMO owns the patents to $CRSP.  I sold my $CRSP shares when I learned how to read'
2020-12-30,b'$EDIT $CRSP $NTLA all dropped in final minutes today while $SGMO gained 1.5%. Smart money quit while they were ahead and moved on to better prospects.  #SGMO #NTLA #EDIT #CRSP #SGMOON'
2020-12-30,"b'Large Print $SGMO Size: 100942 Price: 16.86 Time: 1600 Amount: $1,701,882.12'"
2020-12-30,"b'RT @Biotech2k1: In Biotech, Winners keep winning while laggards; well, linger. Just look at 5 year charts of $SGMO +97% vs $CRSP +937% or $\xe2\x80\xa6'"
2020-12-30,b'@JuergenLabermas The deal breaker was the direct ability to compare the 2 technologies last year at ASH in December of 2019. There was data from both programs for Beta Thal and SCD. The ASH data from $CRSP was light years better then the $SGMO data. The rest is history. Its always in the data.'
2020-12-30,"b'$SGMO #Options #maxpain Chart, Open Interest Chart Update #OptionsTrading #OptionsFlow #optionstrade #optiontrading #stocks #stock #StockMarket #Investment #investing #invest #investor #investors #UOA https://t.co/I8hjTlEqg3 https://t.co/XbIQ5Ep7IB'"
2020-12-30,"b'In Biotech, Winners keep winning while laggards; well, linger. Just look at 5 year charts of $SGMO +97% vs $CRSP +937% or $NK -7.9% vs $FATE +2820%. Maybe at the track you can bet $10 on the 40 to 1 horse, but in biotech the winners run circles around the laggards.'"
2020-12-30,b'Gene tx players 1-10B mkt cap $NTRA $NVTA $ARWR $FATE $BBIO $IOVA $EDIT $PTCT $PACB $ALLO $NTLA $CDNA $ALKS $RCKT $NSTG $BLUE $AGIO $ARCT $SGMO $SRNE $PGEN $RGNX $QURE $DRNA $MYGN $ADVM $FLGT $CLLS $KRYS $PASG\nfeel free to give input https://t.co/ln7esOVk86'
2020-12-30,b'@iceman_cry $SGMO $EDIT $NTLA $BEAM would be equally as good or better than $CRSP at this point'
2020-12-30,"b'RT @manal_mehta: Wow, this is a big deal-If there\xe2\x80\x99s any chance that the IP underlying $CRSP &amp; $VRTX approach to #SickleCell could be cloude\xe2\x80\xa6'"
2020-12-30,b'RT @BiotechAnalysst: @Tijori1 $SGMO CEO speaks about what they are doing\ngene editing IN VIVO\ngene editing EX VIVO\nGene regulation up and d\xe2\x80\xa6'
2020-12-30,b'RT @_B_I_O_T_E_C_H_: Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/insti\xe2\x80\xa6'
2020-12-30,b'RT @BiotechAnalysst: @chiragontwtr @_B_I_O_T_E_C_H_ here you see the 4x edit $SGMO performed for $GILD with ZFN 1.0 !\nthis data led to the\xe2\x80\xa6'
2020-12-30,b'@Biotech2k1 $SGMO has 1000years of safety data you idiot'
2020-12-30,b'RT @mchilberg: Claims $SGMO has no editor and is obsolete.  Ignores truth.  Edited over 100 HIV patients safely.  Picked by $GILD as best i\xe2\x80\xa6'
2020-12-30,b'RT @mchilberg: Did I mention that $PFE has been working with $SGMO #ZFN since 2005 in research.  They also opted to add ZFP-TF gene editing\xe2\x80\xa6'
2020-12-30,b'RT @dkavaichan: $SGMO Theory of a $BIIB buyout:\n\nBiogen in 2018 offered cash and took equity stake in Sangamo to develop several candidates\xe2\x80\xa6'
2020-12-30,b'RT @MaxPowerNGS: @dkavaichan @Rodmon77 Speaking of Gordon Gecko...the best $SGMO play IMO is a $10B PE buy with an asset breakup. GT to $PF\xe2\x80\xa6'
2020-12-30,b'RT @mchilberg: Nice to have Dr Corinne Le Buhan weigh in on $SGMO IP strategy on my recent article.  She took issue with conclusion that SG\xe2\x80\xa6'
2020-12-30,b'RT @mchilberg: Nice to have Dr Corinne Le Buhan weigh in on $SGMO IP strategy on my recent article.  She took issue with conclusion that SG\xe2\x80\xa6'
2020-12-30,b'RT @mchilberg: Did I mention that $PFE has been working with $SGMO #ZFN since 2005 in research.  They also opted to add ZFP-TF gene editing\xe2\x80\xa6'
2020-12-30,"b'@dkavaichan @Rodmon77 Speaking of Gordon Gecko...the best $SGMO play IMO is a $10B PE buy with an asset breakup. GT to $PFE, ZFP-TF to $BIIB, onc cell therapy to $GILD, BCL-11A patents to $SNY or $CRSP. Spin out IVPRP, CARTregs, and mtDNA editing'"
2020-12-30,"b""@Rodmon77 In the words of Gordon Gekko: They will love it at 5.7B, hate it at 10B.\n\nI don't see $BIIB offering that much for $SGMO. You have to give a lil to take a lil. 40 is already a massive premium to the price today. And... https://t.co/CGRY4im7yA"""
2020-12-30,"b'\xf0\x9f\x97\xa3 Follow For\xf0\x9f\x94\xa5 \xf0\x9f\x9a\xa8 What are some of my fav genomic \xf0\x9f\xa7\xac plays?\n$BNGO - Will be picked up by ARKG\n$CRSP - LT\n$PACB - BO target\n$ILMN - Market Leader\n$SGMO - LT, EOY 2021 results\n$ARKG \xe2\x80\x93 Hold\nWatch:\n$NVDA $MSFT $GOOG -  Genomics computational power\n$EDIT $NTLA $NTLA\nWhat are yours?'"
2020-12-30,"b""$SGMO Theory of a $BIIB buyout:\n\nBiogen in 2018 offered cash and took equity stake in Sangamo to develop several candidates. They currently own ~17% of Sangamo.\n\nBiogen is struggling with their current pipeline. There's going... https://t.co/Qpn7rNktTy"""
2020-12-30,b'@ToddWilliamson All or nothing. Added $ZIOP recently. They can manufacture overnight CART using MBIL15 and they infused  on compassionate grounds (nearly dead patients) with early efficacy shown. Hopefully ZIOP $PGEN $SGMO will be the stars of 2021. $TGTX $KPTI $ACAD are 2021 buyout candidates'
2020-12-30,b'Which company updates are you waiting most from #JPM21 ?\nA. $SGMO $PGEN $ZIOP\nB. $KPTI $TGTX $ACAD \n\nIf other companies insert name via response to this tweet.'
2020-12-30,b'I sat there and thought Cathie Wood was nuts until about 4 weeks ago. Then I opened up her Investmen  $BNGO $SGMO $PRNT https://t.co/9W7sSbe9Ym'
2020-12-30,b'RT @JacobPlieth: Lots of quiet dealmaking in Treg cells of late $SGMO $TXCL.PA https://t.co/9tsNwIQUFH'
2020-12-30,b'RT @mchilberg: Nice to have Dr Corinne Le Buhan weigh in on $SGMO IP strategy on my recent article.  She took issue with conclusion that SG\xe2\x80\xa6'
2020-12-30,"b'Nice to have Dr Corinne Le Buhan weigh in on $SGMO IP strategy on my recent article.  She took issue with conclusion that SGMO owned more IP than $CRSP $EDIT $NTLA combined though considered SGMO somewhat hidden IP strategy ""smart"".  See 2018 exec summary https://t.co/Q9rbWwX8IX'"
2020-12-30,"b""RT @chiragontwtr: $SGMO\nThere can't be a better fit for this description."""
2020-12-30,"b""Commented on $SGMO - Sangamo: 'Good Companies Get Bought, Not Sold'. https://t.co/knac9JaCmS"""
2020-12-30,"b""$SGMO\nThere can't be a better fit for this description. https://t.co/4BUyUstqBy"""
2020-12-30,b'RT @VelocirapmTOR: Was hoping for an opportunity like this to get into $ARKG . I believe in Cathie\xe2\x80\x99s thesis for biopharma and beyond. She s\xe2\x80\xa6'
2020-12-30,b'RT @VelocirapmTOR: Was hoping for an opportunity like this to get into $ARKG . I believe in Cathie\xe2\x80\x99s thesis for biopharma and beyond. She s\xe2\x80\xa6'
2020-12-30,"b'@b_seagle The recent moves in small cap bios $CRSP $EDIT $MRNA $NVAX $PSNL $SGMO $STOK $NTLA etc remind me of the roaring 99/2000 genomics stocks $MYGN, Celera, Human Genome Sciences et al. Remember those?  That ended very poorly &amp; set me back a few years but not this time....'"
2020-12-30,"b'@Pharmdca $SGMO, at least until the last two weeks'"
2020-12-30,"b'Tues (12/29/20) Green to Red greatest % below the opening 30-min high &amp; trading range &lt; 20% (Min $5, Vol &gt; 750K, Opt Vol in any strike &gt; 250): $FLNT $VFF $TCS $CRSR $SGMO $ROOT $APPN $VKTX $RRC $SSYS $VECO $WDC $NET $MAC $CCL $COG $SAVE $AAL $JBLU $GDDY $SBSW $UAL $DAL $WPM $LIN https://t.co/Xnz6zhUdM3'"
2020-12-30,b'RT @InvestorVenture: U.S. confirms first case of the new Covid strain discovered in UK \n$APT $AHPI $LAKE $OPK $KODK $BVXV $CODX $ALT $EARS\xe2\x80\xa6'
2020-12-30,"b'Tues (12/29/20) greatest % below the opening 30-min low, G/L % in final 30-Min &amp; Trading range % (Min $5, Vol 750K, Opt Vol in any strike 500): $FLNT $DDD $ORBC $DM $BLNK $RVP $ROOT $SGMO $NBLX $VNO $CRSR $VFF $MAC $RRC $LITE $SRNE $AMRS $VUZI $APT $APPN $RAD $RMG $WDC $BXP $REGI https://t.co/KB2I14Atw5'"
2020-12-30,b'U.S. confirms first case of the new Covid strain discovered in UK \n$APT $AHPI $LAKE $OPK $KODK $BVXV $CODX $ALT $EARS $THMO $ABT $BNTX $APM $BCRX $VXRT $SRNE $ABUS $MRNA $NVAX $INO $GILD $DVAX $QDEL $ABBV $AZN $VERU $PFE $MRK $JNJ $CRSP $SGMO $AMRN $TRVN\nhttps://t.co/CsmNWXkDPn'
2020-12-30,b'Top 15 Pharmaceuticals stocks with market cap over 1 billion in 5 days. \n\nhttps://t.co/PRTWV2hmKh\n\n$PMVP $ENDP $ARVN $AVIR $SUPN $SGMO $PACB $ITCI $ABMD $TNDM $RPRX $RETA $ANNX $HRTX $ZNTL\n\n\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80\xf0\x9f\x9a\x80 https://t.co/DaLvE3P8RQ'
2020-12-30,"b'RT @manal_mehta: Wow, this is a big deal-If there\xe2\x80\x99s any chance that the IP underlying $CRSP &amp; $VRTX approach to #SickleCell could be cloude\xe2\x80\xa6'"
2020-12-29,"b'Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $ostk $ARCT $NNOX $PRPL $MSTR $FUTU $SGMO $OPK $FGEN https://t.co/k3uyuEbRpJ'"
2020-12-29,b'RT @InvestorVenture: U.S. confirms first case of the new Covid strain discovered in UK \n$APT $AHPI $LAKE $OPK $KODK $BVXV $CODX $ALT $EARS\xe2\x80\xa6'
2020-12-29,b'RT @InvestorVenture: U.S. confirms first case of the new Covid strain discovered in UK \n$APT $AHPI $LAKE $OPK $KODK $BVXV $CODX $ALT $EARS\xe2\x80\xa6'
2020-12-29,b'U.S. confirms first case of the new Covid strain discovered in UK \n$APT $AHPI $LAKE $OPK $KODK $BVXV $CODX $ALT $EARS $THMO $ABT $BNTX $APM $BCRX $VXRT $SRNE $ABUS $MRNA $NVAX $INO $GILD $DVAX $QDEL $ABBV $AZN $VERU $PFE $MRK $JNJ $CRSP $SGMO $AMRN $TRVN\nhttps://t.co/X5Rf4mADza'
2020-12-29,b'@srqstockpicker Same my friend! $TRIL $TCON $ONCT $CRIS $SRPT $GME and your favorite $SGMO here.'
2020-12-29,"b'RT @_B_I_O_T_E_C_H_: Mikael Dolsten - $PFE Pfizer Inc. - Chief Scientific Officer and President of Worldwide Research, Development &amp; Medica\xe2\x80\xa6'"
2020-12-29,"b'RT @_B_I_O_T_E_C_H_: think we hear a new deal with $PFE on #ALS next\n$SGMO says on #ALS ""As regards the C9ORF all I can tell you is $PFE Pf\xe2\x80\xa6'"
2020-12-29,b'RT @_B_I_O_T_E_C_H_: Truist Research activities for C9ORF72 gene regulation therapy for #ALS have been completed in\ncollab with $PFE and th\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: $BIIB $NVS is about Pan-Allele ZFP #transcription #factors\n \nTranscription factors do #not cause double-stranded brake\xe2\x80\xa6'
2020-12-29,b'RT @mchilberg: Did I mention that $PFE has been working with $SGMO #ZFN since 2005 in research.  They also opted to add ZFP-TF gene editing\xe2\x80\xa6'
2020-12-29,b'$SGMO Has An Excellent #Technical Analysis Score (TA Score). Breakdown Of 3 Categories: #candle score Good; moving average score Excellent; #momentum score Good #stocks #stock #StockMarket #Investment #investing https://t.co/I8hjTlEqg3 https://t.co/hpqizKlu5J'
2020-12-29,"b'Was hoping for an opportunity like this to get into $ARKG . I believe in Cathie\xe2\x80\x99s thesis for biopharma and beyond. She should, however consider revising her position in $SGMO or at least ZFN as a transformative tech. Would love to see her compare v CRISPR. In at 93.6.'"
2020-12-29,b'RT @_B_I_O_T_E_C_H_: So $SGMO owns the #CRISPR #patents covering some of the IP $CRSP is trying to use?\n\nhttps://t.co/bUjKcN0NHM'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay\xe2\x80\xa6'
2020-12-29,b'RT @mchilberg: Claims $SGMO has no editor and is obsolete.  Ignores truth.  Edited over 100 HIV patients safely.  Picked by $GILD as best i\xe2\x80\xa6'
2020-12-29,b'RT @mchilberg: Did I mention that $PFE has been working with $SGMO #ZFN since 2005 in research.  They also opted to add ZFP-TF gene editing\xe2\x80\xa6'
2020-12-29,b'RT @mchilberg: Saw another claim from B2K that $SGMO is obsolete and failed to get a drug in 25 yrs.  Context: \n- Human Genome Project comp\xe2\x80\xa6'
2020-12-29,b'Stocks to watch $uavs $cmps $gme $vxrt $wing $sgmo &amp; $BIOL BIOLASE INC. https://t.co/mh9yMraMLE'
2020-12-29,"b'@mchilberg Investments in past 30 yrs allow them to bring more effective drugs to patients. Has the most advanced pipeline drugs than any other RNAi/antisense companies. More drugs will be approved in the next 2-3 years. IMO, $sgmo will do the same! $ions'"
2020-12-29,b'Did I mention that $PFE has been working with $SGMO #ZFN since 2005 in research.  They also opted to add ZFP-TF gene editing for ALS in 2018 after working with Sangamo editor for 13 yrs.  #Factsnotfiction https://t.co/jsk964mXlF'
2020-12-29,"b'$SGMO is today ranked #5 in the Daily Gambiste Mid Cap rating. Sangamo Therapeutics, Inc. - Common Stock is today top rated. Check the full Gambiste long term ratings here: https://t.co/RA0LXyNU1n'"
2020-12-29,b'RT @mchilberg: Saw another claim from B2K that $SGMO is obsolete and failed to get a drug in 25 yrs.  Context: \n- Human Genome Project comp\xe2\x80\xa6'
2020-12-29,b'RT @mchilberg: Claims $SGMO has no editor and is obsolete.  Ignores truth.  Edited over 100 HIV patients safely.  Picked by $GILD as best i\xe2\x80\xa6'
2020-12-29,"b'Mid-day Green to Red greatest % below the opening 30-min high &amp; trading range &lt; 20% (Min $5, Vol &gt; 750K, Opt Vol in any strike &gt; 250): $VFF $SGMO $CRSR $EXPI $ROOT $LAC $NKLA $WISH $W $WKHS $VKTX $RRC $OSTK $BB $BYND $WDC $MAC $NET $BEKE $OXY $MRO $AAL https://t.co/I6I2Q56vvq'"
2020-12-29,b'RT @mchilberg: Couple charts worth noting for $SGMO:\n- daily shows retrace back to $16 to retest upper trend\n- wkly shows support around $1\xe2\x80\xa6'
2020-12-29,b'RT @mchilberg: Claims $SGMO has no editor and is obsolete.  Ignores truth.  Edited over 100 HIV patients safely.  Picked by $GILD as best i\xe2\x80\xa6'
2020-12-29,"b""@mchilberg Perhaps someone has some shorts to cover or some CRSP to offload before the market accepts the reality of $SGMO's superiority?"""
2020-12-29,b'RT @_B_I_O_T_E_C_H_: So $SGMO owns the #CRISPR #patents covering some of the IP $CRSP is trying to use?\n\nhttps://t.co/bUjKcN0NHM'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/insti\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: So $SGMO owns the #CRISPR #patents covering some of the IP $CRSP is trying to use?\n\nhttps://t.co/bUjKcN0NHM'
2020-12-29,"b'Sonia Vallabh, PhD, #Broad Institute of #MIT and #Harvard\n\nAssessing efficacy of $SGMO zinc-finger repressors of prion protein as a therapeutic for #prion disease\nreduce PrP\n\nhttps://t.co/BOOi0KQxsZ'"
2020-12-29,"b'RT @mchilberg: @_B_I_O_T_E_C_H_ The CRISPR-Cas9 system is inherently more prone to off-target effects compared to ZFNs or TALENs, because t\xe2\x80\xa6'"
2020-12-29,b'RT @_B_I_O_T_E_C_H_: What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: So $SGMO owns the #CRISPR #patents covering some of the IP $CRSP is trying to use?\n\nhttps://t.co/bUjKcN0NHM'
2020-12-29,b'Claims $SGMO has no editor and is obsolete.  Ignores truth.  Edited over 100 HIV patients safely.  Picked by $GILD as best in class ex vivo editor.  Only editor to successfully edit humans in vivo.  Picked by $NVS $BIBB just this year for #CNS.  #Factsnotfiction'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/insti\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay\xe2\x80\xa6'
2020-12-29,b'RT @mchilberg: Saw another claim from B2K that $SGMO is obsolete and failed to get a drug in 25 yrs.  Context: \n- Human Genome Project comp\xe2\x80\xa6'
2020-12-29,"b""Saw another claim from B2K that $SGMO is obsolete and failed to get a drug in 25 yrs.  Context: \n- Human Genome Project completed in 2003\n- Sequencing costs didn't get to under $1k until 2015\nBoth required to enable all editors.  Careful who you follow\nhttps://t.co/ObyDziqDN9 https://t.co/tkc4kFIaKi"""
2020-12-29,b'Couple charts worth noting for $SGMO:\n- daily shows retrace back to $16 to retest upper trend\n- wkly shows support around $15.70 https://t.co/A3BxOrPkNO'
2020-12-29,b'RT @Biotech2k1: $CRSP is 7 years old and has already very powerful phase 1 data while $SGMO is now 25 years old and still has no functional\xe2\x80\xa6'
2020-12-29,b'That leaves ex vivo gene editing for which there is a crowd chasing the same targets... not to mention there are other gene editing modalities that can and have accomplished the same task $CLLS $SGMO $DTIL $BLUE'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/insti\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay\xe2\x80\xa6'
2020-12-29,b'Gene therapy / gene editing stocks on sale today with rest of biotech. $edit $fate $sgmo $crsp $ntla'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/insti\xe2\x80\xa6'
2020-12-29,"b'$CRSP is 7 years old and has already very powerful phase 1 data while $SGMO is now 25 years old and still has no functional gene editor. You get what you pay for. I would not own any of them up here, but clearly, one of these should be dumped.'"
2020-12-29,"b""RT @mchilberg: After the ARK thread yesterday, I thought I'd do a head to head comparison of $SGMO and $EDIT.  I try to do this to test my\xe2\x80\xa6"""
2020-12-29,b'RT @_B_I_O_T_E_C_H_: So $SGMO owns the #CRISPR #patents covering some of the IP $CRSP is trying to use?\n\nhttps://t.co/bUjKcN0NHM'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: So $SGMO owns the #CRISPR #patents covering some of the IP $CRSP is trying to use?\n\nhttps://t.co/bUjKcN0NHM'
2020-12-29,b'Morning Movers\n\n$AMPH\n$CANG\n$HGEN\n$EH\n$NNDM\n$MNSO\n$UAVS\n$SGMO\n$LAC\n$PSTX\n$FUSE\n$FUBO\n$NKLA https://t.co/URCeZj28Kj'
2020-12-29,"b'$MRK, $CVS and $SGMO charts indicate they\xe2\x80\x99re moving higher.'"
2020-12-29,b'RT @bill75331820: @_B_I_O_T_E_C_H_ Do you mean $sgmo owned the patent of certain pam sequence for certain crispr which target the bcl11a ge\xe2\x80\xa6'
2020-12-29,"b""Sangamo $SGMO up 5% premarket, repeat of last tuesday??? My only regret is not selling weed to high schoolers to buy more 1/15/21 30c 's #sgmo #moon #sgmoon"""
2020-12-29,b'@_B_I_O_T_E_C_H_ Do you mean $sgmo owned the patent of certain pam sequence for certain crispr which target the bcl11a gene? Other company could still develop other pam sequences for different crispr proteins to target the same gene?'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/insti\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/insti\xe2\x80\xa6'
2020-12-29,b'RT @_B_I_O_T_E_C_H_: What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay\xe2\x80\xa6'
2020-12-29,b'What\xe2\x80\x99s BCL11A promotor gene? #sicklecell \n$SGMO ownes the IP to #CRISPR BCL11A\n$CRSP crisprs BCL11A\n $Kite had to pay Memorial Sloan Kettering  752 million for IP #infringement surrounding Yescarta. That was after Gilead paid 11.9 billion to acquire Kite\nhttps://t.co/bUjKcN0NHM https://t.co/7cAKQncxFi'
2020-12-29,"b'Crispr patents by institution.  table by IPlytics showing the # of #crispr #patents owned by different companies/institutions.\n\nThe first two companies are big agra\n\nThe next 4 are UCSF, Harvard, MIT, UPenn\n\nRight after that is $SGMO\n\n$CRSP isn\xe2\x80\x99t even on the goddamn map. https://t.co/5riuIJBXZY'"
2020-12-29,b'So $SGMO owns the #CRISPR #patents covering some of the IP $CRSP is trying to use?\n\nhttps://t.co/bUjKcN0NHM'
2021-01-08,"b""genomics continue to blast.  \n\n$ARKG $TWST $CRSP $EDIT $PACB $PSNL etc etc etc.\n\ncontinue to hold $SGMO,,,,it's undervalued by a lot."""
2021-01-08,b'RT @mattyjc: This is the weirdest piece about $SGMO (originally linked on IV). \nI can\xe2\x80\x99t tell if it\xe2\x80\x99s computer generated or shorts are getti\xe2\x80\xa6'
2021-01-08,b'This is the weirdest piece about $SGMO (originally linked on IV). \nI can\xe2\x80\x99t tell if it\xe2\x80\x99s computer generated or shorts are getting desperate? It vaguely references revenue downgrades by \xe2\x80\x9cthe analysts\xe2\x80\x9d (not cited) then repeatedly says things are bad ?? https://t.co/SZvzBZsjA8'
2021-01-08,"b'RT @Zero_Hegde: adamfeuerstein tweets\n\n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""\n\n( $SGMO does this )'"
2021-01-08,b'@RNAiAnalyst Or you could buy $SGMO who will have POC data later this year with an upstream approach? https://t.co/qxinozi488\nAlthough these days it is easier to just sell the concept for billions of dollars and worry about details of actually developing the product later.'
2021-01-08,b'@dhovekamp42 $SGMO is already years ahead in an upstream approach of directly editing Treg cells?\nhttps://t.co/qxinozi488\nTheir 1st product is already set to enter trials this year'
2021-01-08,"b'RT @GambisteFinance: Morning Most Tweeted Mid Caps, check out Gambiste Top 10: $SBS $MGNI $WKHS $Ostk $MSTR $FCEL $AG $FGEN $SGMO $HYLN htt\xe2\x80\xa6'"
2021-01-08,"b'RT @GambisteFinance: Morning Most Tweeted Mid Caps, check out Gambiste Top 10: $SBS $MGNI $WKHS $Ostk $MSTR $FCEL $AG $FGEN $SGMO $HYLN htt\xe2\x80\xa6'"
2021-01-08,"b'RT @juliaskripkaser: What\xe2\x80\x99s in the theme here? $sgmo $reta $ino $cydy, the leftover \xf0\x9f\x97\x91 like $cvm $nwbo $avxl, and $tsla(\xf0\x9f\x98\xb1\xf0\x9f\xa4\xa6\xe2\x80\x8d\xe2\x99\x80\xef\xb8\x8f\xf0\x9f\x98\x89\xf0\x9f\x99\x83\xf0\x9f\x98\x9b)? Happy new\xe2\x80\xa6'"
2021-01-08,"b'Morning Most Tweeted Mid Caps, check out Gambiste Top 10: $SBS $MGNI $WKHS $Ostk $MSTR $FCEL $AG $FGEN $SGMO $HYLN https://t.co/k3uyuEbRpJ'"
2021-01-08,"b'RT @juliaskripkaser: What\xe2\x80\x99s in the theme here? $sgmo $reta $ino $cydy, the leftover \xf0\x9f\x97\x91 like $cvm $nwbo $avxl, and $tsla(\xf0\x9f\x98\xb1\xf0\x9f\xa4\xa6\xe2\x80\x8d\xe2\x99\x80\xef\xb8\x8f\xf0\x9f\x98\x89\xf0\x9f\x99\x83\xf0\x9f\x98\x9b)? Happy new\xe2\x80\xa6'"
2021-01-08,"b'What\xe2\x80\x99s in the theme here? $sgmo $reta $ino $cydy, the leftover \xf0\x9f\x97\x91 like $cvm $nwbo $avxl, and $tsla(\xf0\x9f\x98\xb1\xf0\x9f\xa4\xa6\xe2\x80\x8d\xe2\x99\x80\xef\xb8\x8f\xf0\x9f\x98\x89\xf0\x9f\x99\x83\xf0\x9f\x98\x9b)? Happy new year! https://t.co/SYh2V3uZd5'"
2021-01-08,"b'RT @Tickeron: $SGMO enters an Uptrend because Momentum Indicator exceeded the 0 level on December 9, 2020. View odds for this and other ind\xe2\x80\xa6'"
2021-01-08,"b'$SGMO enters an Uptrend because Momentum Indicator exceeded the 0 level on December 9, 2020. View odds for this and other indicators: https://t.co/GJjOIa7j6r #SangamoTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/TXcCE7uivK'"
2021-01-08,b'@adamfeuerstein @zbiotech $SGMO will be the last standing.'
2021-01-08,b'RT @mchilberg: The Stifel $SGMO comments context (the most recent initiation).  They put a LoA for MPS2 at 10% projecting revs in C24.  Ver\xe2\x80\xa6'
2021-01-08,b'RT @mchilberg: The Stifel $SGMO comments context (the most recent initiation).  They put a LoA for MPS2 at 10% projecting revs in C24.  Ver\xe2\x80\xa6'
2021-01-08,b'RT @MaxPowerNGS: @_B_I_O_T_E_C_H_ Adam just realized what in-vivo editing could enable. He didn\xe2\x80\x99t understand what it meant when $SGMO succe\xe2\x80\xa6'
2021-01-08,b'RT @_B_I_O_T_E_C_H_: looks like $SGMO can open the #DMD fridge'
2021-01-08,b'RT @MaxPowerNGS: @_B_I_O_T_E_C_H_ Adam just realized what in-vivo editing could enable. He didn\xe2\x80\x99t understand what it meant when $SGMO succe\xe2\x80\xa6'
2021-01-08,"b'RT @_B_I_O_T_E_C_H_: yes ""in vivo gene editing""  thats HUGE  and thats what $SGMO longs are here for ...\nnot for the gene therapy hedges  b\xe2\x80\xa6'"
2021-01-08,"b'RT @Zero_Hegde: adamfeuerstein tweets\n\n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""\n\n( $SGMO does this )'"
2021-01-08,"b'RT @BiotechAnalysst: $SGMO \nAdam Feuerstein says \n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""'"
2021-01-08,b'RT @MaxPowerNGS: @_B_I_O_T_E_C_H_ Adam just realized what in-vivo editing could enable. He didn\xe2\x80\x99t understand what it meant when $SGMO succe\xe2\x80\xa6'
2021-01-08,"b""RT @yusufhameed: $SRPT failures is $SGMO gain?  Novartis believes Sangamo's technology can solve that type of problem, and aims to go after\xe2\x80\xa6"""
2021-01-08,b'RT @mchilberg: This immediately made me remember one of my theses for $SGMO:  They appear likely to have a lower failure rate due to their\xe2\x80\xa6'
2021-01-08,b'RT @Biotech2050: #JPM21 #JPMorgan $BMY $TGTX $XLRN $KPTI $PGEN $ZIOP $ACAD $HALO $SGMO \n\nWhich other companies\xe2\x80\x99 presentations are you looki\xe2\x80\xa6'
2021-01-07,"b'RT @GambisteFinance: Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $SGMO $WKHS $FCEL $MGNI $MSTR $NIU $HYLN $APHA $BIGC https:/\xe2\x80\xa6'"
2021-01-07,"b'Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $SGMO $WKHS $FCEL $MGNI $MSTR $NIU $HYLN $APHA $BIGC https://t.co/k3uyuEbRpJ'"
2021-01-07,b'This immediately made me remember one of my theses for $SGMO:  They appear likely to have a lower failure rate due to their investments in delivery and molecular engineering.  Need to hire more #DeliverySciences pros https://t.co/vJJr1dGRSV'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: #DMD $DTIL  with $LLY\n$SGMO with .... ?'
2021-01-07,"b""RT @yusufhameed: $SRPT failures is $SGMO gain?  Novartis believes Sangamo's technology can solve that type of problem, and aims to go after\xe2\x80\xa6"""
2021-01-07,"b""$SRPT failures is $SGMO gain?  Novartis believes Sangamo's technology can solve that type of problem, and aims to go after larger genes implicated in neurodevelopment diseases. https://t.co/1321I0upb6"""
2021-01-07,b'RT @_B_I_O_T_E_C_H_: looks like $SGMO can open the #DMD fridge https://t.co/29g3GHnl6f'
2021-01-07,b'RT @MaxPowerNGS: @_B_I_O_T_E_C_H_ Adam just realized what in-vivo editing could enable. He didn\xe2\x80\x99t understand what it meant when $SGMO succe\xe2\x80\xa6'
2021-01-07,b'RT @BudRante: Gotta chilllaaaax\nBreakthrough #diagnostics \nIsolates #STRUCTURAL Variations \n$BNGO #Saphyr \nAbnormal #genome structures dete\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: looks like $SGMO can open the #DMD fridge https://t.co/29g3GHnl6f'
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: Goldman Sachs: \n#DMD gene #therapy vs. #DMD gene #editing?  \n\nTo-date, we have seen encouraging DMD gene therapy data\xe2\x80\xa6'"
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: Goldman Sachs: \n#DMD gene #therapy vs. #DMD gene #editing?  \n\nTo-date, we have seen encouraging DMD gene therapy data\xe2\x80\xa6'"
2021-01-07,b'RT @_B_I_O_T_E_C_H_: @MauriceOnTW Correction of dystrophin expression in cells from #DMD Duchenne muscular  dystrophy patients through geno\xe2\x80\xa6'
2021-01-07,b'RT @Biotech2050: @_B_I_O_T_E_C_H_ Does $SGMO still have the DMD solution in the fridge? Maybe they can help $SRPT once ZFN2.2 is up and run\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: #DMD $DTIL  with $LLY\n$SGMO with .... ?'
2021-01-07,b'#DMD $DTIL  with $LLY\n$SGMO with .... ?'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: so $LLY does DMD gene editing with $DTIL\nwonder who will be the $SGMO #DMD partner now ...\nremember Sangamo stated the\xe2\x80\xa6'
2021-01-07,b'looks like $SGMO can open the #DMD fridge https://t.co/29g3GHnl6f'
2021-01-07,b'RT @MaxPowerNGS: @_B_I_O_T_E_C_H_ Adam just realized what in-vivo editing could enable. He didn\xe2\x80\x99t understand what it meant when $SGMO succe\xe2\x80\xa6'
2021-01-07,"b'$SGMO #Options #maxpain Chart, Open Interest Chart Update #OptionsTrading #OptionsFlow #optionstrade #optiontrading #stocks #stock #StockMarket #Investment #investing #invest #investor #investors #UOA https://t.co/5JE2nlrW3B https://t.co/SmXbyjUMle'"
2021-01-07,b'Now if $SGMO could become a $CRSP someday...gotta be room for both in that field. The FUTCHA Marty...the FUUTCHA!!'
2021-01-07,b'LOOKS LIKE SOME SIZE COMING INTO THE PRINTS HERE .. $SGMO .. HEADS UP'
2021-01-07,b'RT @BudRante: Gotta chilllaaaax\nBreakthrough #diagnostics \nIsolates #STRUCTURAL Variations \n$BNGO #Saphyr \nAbnormal #genome structures dete\xe2\x80\xa6'
2021-01-07,b'Gotta chilllaaaax\nBreakthrough #diagnostics \nIsolates #STRUCTURAL Variations \n$BNGO #Saphyr \nAbnormal #genome structures determines if #Cancer  is a strong possibility or not\n\nNot even \n$SGMO\n$BLUE\n$ILMN\n$PACB \nNot capable\n@cnnbrk @CNBCFastMoney @SquawkStreet @CNBCClosingBell https://t.co/WZVoXIg28d https://t.co/086wTQufCq'
2021-01-07,b'@_B_I_O_T_E_C_H_ Adam just realized what in-vivo editing could enable. He didn\xe2\x80\x99t understand what it meant when $SGMO successfully conducted the first in man in vivo editing in 2017. He is still learning... \nhttps://t.co/44Gw5sEkeB'
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: @JacobPlieth TRUIST spoke with CFO, Sung Lee, who told us his departure from Sangamo (effective Feb 1) was for family\xe2\x80\xa6'"
2021-01-07,"b""@pawcio2009 thank you for the list\n\n$PAVM $ONCT $AFMD $SIOX $XAIR $PDSB $ADAP $APTO $CRIS $SGMO $TCON $CYCC $LPTX $KALA $TRIL $NWBO $ANVS $KPTI $MREO $PIRS $TGTX $VBIV $XERS $ARWR $ATNM $BCRX $BNGO $EVFM\n\nhttps://t.co/lMqxB0FAUJ\n\n($NWBO doesn't show)"""
2021-01-07,b'! $GOOGL $DOW $MSFT $AAPL $ZM $ZS $AMD $M $TSLA #MUSK $GLD $SLV $TVIX $CRSP $SGMO $NFLX $DIS $GOOGL $FB $IBM $NVDA $PPLT $CLDR $OKTA $SNOW $NNOX $AMC $T $NOK $GE $CAT  $SPY $ORCL $COST $AMZN $WMT #COVID #VACCINE #MRNA $PFE $NVAX https://t.co/Au681mAKkq'
2021-01-07,b'RT @biotech_junkie: $SGMO is the cheapest CRISPR stock\nits has CRISPR ZFN 2.0 technology  that can regulate genes rather than only cut \n$CR\xe2\x80\xa6'
2021-01-07,"b'RT @Zero_Hegde: adamfeuerstein tweets\n\n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""\n\n( $SGMO does this )'"
2021-01-07,b'RT @Biotech2050: #JPM21 #JPMorgan $BMY $TGTX $XLRN $KPTI $PGEN $ZIOP $ACAD $HALO $SGMO \n\nWhich other companies\xe2\x80\x99 presentations are you looki\xe2\x80\xa6'
2021-01-07,b'@adamfeuerstein @bradloncar Yes... How about this acronym $SGMO'
2021-01-07,"b""$SGMO sad to say this but it's underperforming big time the other GE, GT stocks"""
2021-01-07,b'RT @Biotech2k1: Saying a fond farewell to $CRSP. Its been a wild ride and a lot of fun getting bash by $SGMO fanatics. I first bought it at\xe2\x80\xa6'
2021-01-07,"b'$SGMO is today ranked #1 in the Daily Gambiste Mid Cap rating. Sangamo Therapeutics, Inc. - Common Stock is today top rated. Check the full Gambiste long term ratings here: https://t.co/RA0LXyNU1n'"
2021-01-07,b'$MOR New CFO of #Morphosys had family reasons to leave $SGMO \xf0\x9f\x91\x87 https://t.co/goDCFZf5pT'
2021-01-07,"b""RT @JonathanProulx: @ebensteezin @mchilberg Moving to $4B company (MorphoSys), so I'm not sure the departure reflects negatively on Sangamo\xe2\x80\xa6"""
2021-01-07,"b'RT @BiotechAnalysst: $SGMO \nAdam Feuerstein says \n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""'"
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: yes ""in vivo gene editing""  thats HUGE  and thats what $SGMO longs are here for ...\nnot for the gene therapy hedges  b\xe2\x80\xa6'"
2021-01-07,"b""Rose Above Previous Day's High today: $WEYS $SGMO $PICO $DJD $ISDR $DPW $KIDS $ISTR $JNPR $LJPC $ICON $INTC $SLDB $AYLA $JCE $TRX $BOUT $FFTG $JHI $SBBP ... https://t.co/TBYRpvrFqi"""
2021-01-07,b'@AlbertBourla @pfizer How will @SangamoTx $SGMO fund the infinite pipeline of #GeneTherapy #GeneEditing candidate opportunities? Time for a merger?'
2021-01-07,b'RT @mchilberg: Final thought: This rpt values $SGMO at $16 on #GeneTherapy programs which are least valuable.  M&amp;A will put lions sh of val\xe2\x80\xa6'
2021-01-07,b'RT @group_a3: Sending in backup troops aid Washington D.C.... Riot-related stocks on the move: $LLLI  $DTII  $DGLY  $SAFS  https://t.co/qDm\xe2\x80\xa6'
2021-01-07,b'RT @group_a3: Sending in backup troops aid Washington D.C.... Riot-related stocks on the move: $LLLI  $DTII  $DGLY  $SAFS  https://t.co/qDm\xe2\x80\xa6'
2021-01-07,b'Sending in backup troops aid Washington D.C.... Riot-related stocks on the move: $LLLI  $DTII  $DGLY  $SAFS  https://t.co/qDmLr4aBF1      $SOS  $FTFT  $TSLA  $APPL  $PLUG  $MARA  $SNDL  $SGMO  $NAKD  $CBAT'
2021-01-07,"b""@ebensteezin @mchilberg Moving to $4B company (MorphoSys), so I'm not sure the departure reflects negatively on Sangamo. $SGMO $MOR\n\nhttps://t.co/GZtmxKZRHG"""
2021-01-07,"b'RT @BiotechAnalysst: $SGMO \nAdam Feuerstein says \n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""'"
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: yes ""in vivo gene editing""  thats HUGE  and thats what $SGMO longs are here for ...\nnot for the gene therapy hedges  b\xe2\x80\xa6'"
2021-01-07,"b'RT @BiotechAnalysst: $SGMO \nAdam Feuerstein says \n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""'"
2021-01-07,b'RT @Biotech2050: #JPM21 #JPMorgan $BMY $TGTX $XLRN $KPTI $PGEN $ZIOP $ACAD $HALO $SGMO \n\nWhich other companies\xe2\x80\x99 presentations are you looki\xe2\x80\xa6'
2021-01-07,"b'$SGMO \nAdam Feuerstein says \n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""'"
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: BREAKING: $SGMO  Ed Rebar says on in vivo gene editing update:\n""We see ""#evidence of #success"" in MPS-II trial, incl.\xe2\x80\xa6'"
2021-01-07,b'RT @BiotechAnalysst: $SGMO These results demonstrate efficient functional correction of #CFTR and provide          a platform for further\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: $SGMO HIGHLY SPECIFIC ZFN-BASED HSC GENE EDITING THERAPIES IDENTIFIED BY IN VIVO BARCODE NANOPARTICLE SCREENS AND RATI\xe2\x80\xa6'
2021-01-07,b'RT @Biotech2050: @MitchellReed09 @JohnCendpts @US_FDA @endpts @NIHDirector Zinc fingers summarized here. And $SGMO working on ZFN2.0 which\xe2\x80\xa6'
2021-01-07,"b'RT @mchilberg: Basis of $SGMO in vivo GE in C21? \nPrimary basis is the C19 10k statement, company references and progress noted.  Plan appe\xe2\x80\xa6'"
2021-01-07,b'RT @_B_I_O_T_E_C_H_: Big Report out by William Blair \nUnder the Microscope\nIt\xe2\x80\x99s All in the #Delivery: Understanding\nViral and Nonviral Appr\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: $SGMO says TX200 HLA-A2 CAR-TREGS efficiently #prevent Graft vs Host Disease (#GvHD) and \n#skin transplant #rejection\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: $SGMO CEO speaks about what they are doing\ngene editing IN VIVO\ngene editing EX VIVO\nGene regulation up and down\ninact\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: @mchilberg $SGMO said editing happened .. eff lost on delivery way .. ZFN 2.0 would fix ... \nbut they have more in viv\xe2\x80\xa6'
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: @JacobPlieth TRUIST spoke with CFO, Sung Lee, who told us his departure from Sangamo (effective Feb 1) was for family\xe2\x80\xa6'"
2021-01-07,"b'RT @Zero_Hegde: adamfeuerstein tweets\n\n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""\n\n( $SGMO does this )'"
2021-01-07,"b'RT @Zero_Hegde: adamfeuerstein tweets\n\n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""\n\n( $SGMO does this )'"
2021-01-07,b'#JPM21 #JPMorgan $BMY $TGTX $XLRN $KPTI $PGEN $ZIOP $ACAD $HALO $SGMO \n\nWhich other companies\xe2\x80\x99 presentations are you looking forward too? Will a buyout be announced just before the event? https://t.co/LFwa2F4hGF'
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: yes ""in vivo gene editing""  thats HUGE  and thats what $SGMO longs are here for ...\nnot for the gene therapy hedges  b\xe2\x80\xa6'"
2021-01-07,b'$ISR 1.31? OMG! adding!! MASSIVE NEWS. FDA APPROVED! $10 break easy\n\n$IONS $GBT $XON $CRSP $EDIT $NTLA $PBYI $BMRN $TSRO $CELG $BLUE $ALKS $ALNY $GILD $BIIB $AMGN $SGMO $ONCE $ENDP $PRGO $LCI $COLL $ANIP $MYL $OSUR $PODD $BIO $EW $ABT $MDT $ZIOP $KOOL $SRNE $CLLS $JNJ $MARA $RIOT https://t.co/tX1thF4NYY'
2021-01-07,"b'RT @Getrealorelse: $CRSP +20 to 185.  $ARKG of course pops with it, &gt;100.\n\n$TWST $EDIT $SGMO $PACB'"
2021-01-07,"b'RT @Getrealorelse: $CRSP +20 to 185.  $ARKG of course pops with it, &gt;100.\n\n$TWST $EDIT $SGMO $PACB'"
2021-01-07,"b'$CRSP +20 to 185.  $ARKG of course pops with it, &gt;100.\n\n$TWST $EDIT $SGMO $PACB'"
2021-01-07,"b""$QS $SGMO $SSPK $SKLZ $IPOC huge bags! \nDon't miss out \xf0\x9f\xa5\xb1 https://t.co/O8soht86xQ"""
2021-01-07,b'RT @_B_I_O_T_E_C_H_: did $SGMO perform in vivo gene editing already?'
2021-01-07,b'RT @mchilberg: The Stifel $SGMO comments context (the most recent initiation).  They put a LoA for MPS2 at 10% projecting revs in C24.  Ver\xe2\x80\xa6'
2021-01-07,b'did $SGMO perform in vivo gene editing already?'
2021-01-07,"b'@mchilberg $SGMO said editing happened .. eff lost on delivery way .. ZFN 2.0 would fix ... \nbut they have more in vivo programs HemoB  and MPS1\nso actually this is a platform on its own ,valuation insane\nfunny how exited adam feuerstein is this morning on crispr ""in vivo"" without timeline'"
2021-01-07,b'$ISR with this huge FDA NEWS $3 break is eminent but what if it breaks $15?\xf0\x9f\x92\xb8\n\n$THOR $XBIT $ARQL $FATE $ACHV $OBSV $AGIO $ABEO $RCKT $DTIL $AM $CGC $SESN $SGMO $BMY $GALT $DD $DPLO $THO $JT $JNJ $PFE $LLY $MRK $ROKU $TSLA $FB $MU $SIRI $SPY $UBER $AMZN $JPM #CRYPTO #BITCOIN $F $C https://t.co/uO0IYlTUyz'
2021-01-07,b'RT @mchilberg: The Stifel $SGMO comments context (the most recent initiation).  They put a LoA for MPS2 at 10% projecting revs in C24.  Ver\xe2\x80\xa6'
2021-01-07,b'The Stifel $SGMO comments context (the most recent initiation).  They put a LoA for MPS2 at 10% projecting revs in C24.  Very low valuation inconsistent with value of being first in class with in vivo #IVPRP.  Success with MPSII is an expontential valuation multiplier like Treg https://t.co/6zv2SS46Ch https://t.co/TNeH4vew58'
2021-01-07,"b'RT @BiotechAnalysst: wow $SGMO ""evidence of success"" in vivo gene editing https://t.co/LuZiIrsceh'"
2021-01-07,b'RT @_B_I_O_T_E_C_H_: HCW pointing out unparalleled flexibility in $SGMO Sangamos ZFP platform that is its most meaningful #differentiator p\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: nice to see GoldmanSachs finaly mention $SGMO as a member of the gene editing complex\n$CRSP $NTLA $EDIT $SGMO triggere\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: HCW pointing out unparalleled flexibility in $SGMO Sangamos ZFP platform that is its most meaningful #differentiator p\xe2\x80\xa6'
2021-01-07,b'@Trefis Themes - Gene Editing Portfolio:\nhttps://t.co/BbjBDprQAI\n\n$CRSP $NTLA $BEAM $EDIT $SGMO $VRTX $BLUE\n\n#GeneEditing #investing'
2021-01-07,b'RT @BiotechAnalysst: $SGMO full reseach report #gene #editing FYI:\n$CRSP $EDIT $NTLA $BEAM $FIXX $CLLS \n\nhttps://t.co/0iRbPcXeIx'
2021-01-07,b'$ISR NEWS!!! GONNA break $2 today!\xe2\x9c\x88\xf0\x9f\x8d\xbe\xf0\x9f\x92\xb8\n\n$THOR $XBIT $ARQL $FATE $ACHV $OBSV $AGIO $ABEO $RCKT $DTIL $AM $CGC $SESN $SGMO $BMY $GALT $DD $DPLO $THO $JT $JNJ $PFE $LLY $MRK $ROKU $TSLA $FB $MU $SIRI $SPY $UBER $AMZN $JPM #CRYPTO #BLOCKCHAIN #ICO #BITCOIN $FNMA $DRYS $AMD $F $M https://t.co/wGoLzoXMPh'
2021-01-07,"b'RT @BiotechAnalysst: wow $SGMO ""evidence of success"" in vivo gene editing https://t.co/LuZiIrsceh'"
2021-01-07,b'Look at the put spread on the 15 strike $SGMO (1-15-21) What does that tell you? I know what it tells me.'
2021-01-07,"b'adamfeuerstein tweets\n\n""#In #vivo = in the body #gene #editing, which is #huge, if it works.""\n\n( $SGMO does this )'"
2021-01-07,b'RT @biotech_junkie: $SGMO is the cheapest CRISPR stock\nits has CRISPR ZFN 2.0 technology  that can regulate genes rather than only cut \n$CR\xe2\x80\xa6'
2021-01-07,b'Saying a fond farewell to $CRSP. Its been a wild ride and a lot of fun getting bash by $SGMO fanatics. I first bought it at $25 back in 2018. Today I sold it for $175 for a 600% gain. Time to go and find the next big thing.'
2021-01-07,b'RT @biotech_junkie: $SGMO is the cheapest CRISPR stock\nits has CRISPR ZFN 2.0 technology  that can regulate genes rather than only cut \n$CR\xe2\x80\xa6'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: .@JohnCendpts\n hosting $SGMO CEO and $NVS @ #JPM21 \n\nhttps://t.co/7r5bj1WpLT    #GeneEditing $CRSP $EDIT $NTLA \n\nGene\xe2\x80\xa6'
2021-01-07,b'RT @Biotech2050: @MitchellReed09 @JohnCendpts @US_FDA @endpts @NIHDirector Zinc fingers summarized here. And $SGMO working on ZFN2.0 which\xe2\x80\xa6'
2021-01-07,b'RT @BiotechAnalysst: @Tijori1 $SGMO CEO speaks about what they are doing\ngene editing IN VIVO\ngene editing EX VIVO\nGene regulation up and d\xe2\x80\xa6'
2021-01-07,b'RT @biotech_junkie: @Biotech2k1 @BiotechAnalysst CRISPR can only cut  $SGMO ZFN can cut + up down regulate  silence dimm genes \nCRISPR cant\xe2\x80\xa6'
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: yes ""in vivo gene editing""  thats HUGE  and thats what $SGMO longs are here for ...\nnot for the gene therapy hedges  b\xe2\x80\xa6'"
2021-01-07,b'RT @MaxPowerNGS: @biotech_junkie @Biotech2k1 @BiotechAnalysst ZFP-TF can regulate gene expression; ZFNs cut. There are other ways that Zinc\xe2\x80\xa6'
2021-01-07,b'RT @biotech_junkie: @Biotech2k1 @BiotechAnalysst CRISPR can only cut  $SGMO ZFN can cut + up down regulate  silence dimm genes \nCRISPR cant\xe2\x80\xa6'
2021-01-07,b'RT @manal_mehta: @ChrisHeery @kiranmusunuru @MassGeneralNews @JKeithJoung @HSCRB @VerveTx @davidrliu @RobertLKruse @PrecisionBioSci @KevinA\xe2\x80\xa6'
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: @JacobPlieth TRUIST spoke with CFO, Sung Lee, who told us his departure from Sangamo (effective Feb 1) was for family\xe2\x80\xa6'"
2021-01-07,b'RT @biotech_junkie: @Biotech2k1 @BiotechAnalysst CRISPR can only cut  $SGMO ZFN can cut + up down regulate  silence dimm genes \nCRISPR cant\xe2\x80\xa6'
2021-01-07,"b'RT @manal_mehta: ""important efficacy &amp; safety concerns for #CRISPR-Cas9-based in vivo genome editing...""\n$CRSP vs $SGMO #ZFN h/t @mchilberg\xe2\x80\xa6'"
2021-01-07,b'RT @_B_I_O_T_E_C_H_: $SGMO ZFN 2.0 in vivo gene editing 2020\nEnhanced efficiency of ZFN delivery to\nhepatocytes is critical\nHemA data sugge\xe2\x80\xa6'
2021-01-07,"b'RT @BiotechAnalysst: wow $SGMO ""evidence of success"" in vivo gene editing https://t.co/LuZiIrsceh'"
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: yes ""in vivo gene editing""  thats HUGE  and thats what $SGMO longs are here for ...\nnot for the gene therapy hedges  b\xe2\x80\xa6'"
2021-01-07,"b'yes ""in vivo gene editing""  thats HUGE  and thats what $SGMO longs are here for ...\nnot for the gene therapy hedges  but for in vivo gene editing  ZFN 2.0'"
2021-01-07,b'RT @_B_I_O_T_E_C_H_: $SGMO ZFN 2.0 in vivo gene editing 2020\nEnhanced efficiency of ZFN delivery to\nhepatocytes is critical\nHemA data sugge\xe2\x80\xa6'
2021-01-07,"b'RT @manal_mehta: ""important efficacy &amp; safety concerns for #CRISPR-Cas9-based in vivo genome editing...""\n$CRSP vs $SGMO #ZFN h/t @mchilberg\xe2\x80\xa6'"
2021-01-07,b'RT @biotech_junkie: @Biotech2k1 @BiotechAnalysst CRISPR can only cut  $SGMO ZFN can cut + up down regulate  silence dimm genes \nCRISPR cant\xe2\x80\xa6'
2021-01-07,b'$SGMO Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee https://t.co/qHdm0mxZl8'
2021-01-07,b'$OXFD down for the count. Merger mania in biotech in 2021.\n\n$PGEN $SGMO $CLVS $ICPT are my takeover candidates for 2021\nhttps://t.co/fUjwNBysM0'
2021-01-07,"b'Morning Most Tweeted Mid Caps, check out Gambiste Top 10: $Grwg $MSTR $FCEL $OSTK $TRN $APHA $AG $SBS $WKHS $SGMO https://t.co/k3uyuEbRpJ'"
2021-01-07,b'$SEIC Goldman Buy $70.50 \n$SFT The Benchmark Company Hold \n$SGMO Stifel Hold $16 \n$SPG Evercore ISI In-line $89 \n$SRRK JP Morgan Overweight $59 \n$TEAM Macquarie Outperform \n$TWLO Macquarie Outperform \n$VLDR Citigroup Buy $31 \n$VTR Robert W. Baird Neutral $49'
2021-01-07,"b'RT @JacobPlieth: Now that Sung Lee is moving from the Bay Area to... Planegg, may I wish him all the best and recommend Wirtshaus Br\xc3\xa4ust\xc3\xbcbe\xe2\x80\xa6'"
2021-01-07,b'$ISR beautiful video describing everything\nhttps://t.co/OH5JYKjQZj\n\n$IONS $GBT $XON $CRSP $EDIT $NTLA $PBYI $BMRN $TSRO $CELG $BLUE $ALKS $ALNY $GILD $BIIB $AMGN $SGMO $ONCE $ENDP $PRGO $LCI $COLL $ANIP $MYL $OSUR $PODD $BIO $EW $ABT $MDT $ZIOP $KOOL $SRNE $CLLS $JNJ $MARA $RIOT'
2021-01-07,b'RT @biotech_junkie: @Biotech2k1 @BiotechAnalysst CRISPR can only cut  $SGMO ZFN can cut + up down regulate  silence dimm genes \nCRISPR cant\xe2\x80\xa6'
2021-01-07,b'RT @biotech_junkie: @Biotech2k1 @BiotechAnalysst CRISPR can only cut  $SGMO ZFN can cut + up down regulate  silence dimm genes \nCRISPR cant\xe2\x80\xa6'
2021-01-07,"b'RT @_B_I_O_T_E_C_H_: @JacobPlieth TRUIST spoke with CFO, Sung Lee, who told us his departure from Sangamo (effective Feb 1) was for family\xe2\x80\xa6'"
2021-01-07,"b'RT @JacobPlieth: Now that Sung Lee is moving from the Bay Area to... Planegg, may I wish him all the best and recommend Wirtshaus Br\xc3\xa4ust\xc3\xbcbe\xe2\x80\xa6'"
2021-01-07,"b'@JacobPlieth TRUIST spoke with CFO, Sung Lee, who told us his departure from Sangamo (effective Feb 1) was for family reasons and an opportunity in Europe brings his family closer to home.\nSung told us that he is #sad to leave the company when a lot of #exciting things are happening\nat $SGMO'"
2021-01-07,"b'Now that Sung Lee is moving from the Bay Area to... Planegg, may I wish him all the best and recommend Wirtshaus Br\xc3\xa4ust\xc3\xbcberl, my favourite Planegg eatery https://t.co/4e5DJzYVlh $SGMO $MOR https://t.co/TqgfKJcGRC'"
2021-01-07,b'RT @_B_I_O_T_E_C_H_: .@JohnCendpts\n hosting $SGMO CEO and $NVS @ #JPM21 \n\nhttps://t.co/7r5bj1WpLT    #GeneEditing $CRSP $EDIT $NTLA \n\nGene\xe2\x80\xa6'
2021-01-07,b'RT @StockSponge: $SGMO needs a few more days imo but setting up nicely https://t.co/kztZoyXwLD'
2021-01-07,b'$SGMO needs a few more days imo but setting up nicely https://t.co/kztZoyXwLD'
2021-01-07,b'$SGMO IS TOMORROW OUR DAY !?!?! \xf0\x9f\xa4\x94\xf0\x9f\xa4\x94\xf0\x9f\xa4\x94'
2021-01-07,b'Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee $SGMO https://t.co/08oo7HqPez'
2021-01-07,b'RT @snicobio: $GBIO is dosing 33X more DNA with their liver-directed ctLNPs and achieving &gt;10-fold less factor VIII expression compared to\xe2\x80\xa6'
2021-01-07,b'RT @MaxPowerNGS: @KodyMefford @mchilberg @manal_mehta I think $SGMO have been approached on a buyout...hence the recent language. A new par\xe2\x80\xa6'
2021-01-07,b'RT @InvesToor: $PFE just needs to quit with the acquisitions tease and just buy $SGMO now. At a premium too please.'
2021-01-07,b'RT @biotech_junkie: $SGMO is the cheapest CRISPR stock\nits has CRISPR ZFN 2.0 technology  that can regulate genes rather than only cut \n$CR\xe2\x80\xa6'
2021-01-07,b'RT @biotech_junkie: i think $SGMO will be bought out for its $GENE $EDIT ing \nby $PFE or $GILD within the next few days / weeks'
2021-01-07,"b""$SGMO's price moved above its 50-day Moving Average on December 10, 2020. View odds for this and other indicators: https://t.co/c0cJDKoTDA #SangamoTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today https://t.co/XF18Ljefiu"""
2021-01-06,"b'Evening Most Tweeted Mid Caps, check out Gambiste Top 10: $SGMO $apha $CRON $GRWG $fcel $OSTK $wkhs $hyln $FSR https://t.co/k3uyuEtshh'"
